KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Sarepta Therapeutics (SRPT) Accumulated Depreciation & Amortization (2016 - 2025)

Sarepta Therapeutics has reported Accumulated Depreciation & Amortization over the past 15 years, most recently at $44.5 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 18.02% year-over-year to $44.5 million; the TTM value through Dec 2025 reached $44.5 million, up 18.02%, while the annual FY2025 figure was $44.5 million, 18.02% up from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $44.5 million at Sarepta Therapeutics, up from $37.7 million in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $112.6 million in Q4 2021 and troughed at $37.7 million in Q4 2024.
  • A 5-year average of $56.2 million and a median of $44.4 million in 2023 define the central range for Accumulated Depreciation & Amortization.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: surged 48.15% in 2021 and later tumbled 62.83% in 2022.
  • Year by year, Accumulated Depreciation & Amortization stood at $112.6 million in 2021, then tumbled by 62.83% to $41.9 million in 2022, then rose by 6.05% to $44.4 million in 2023, then dropped by 15.03% to $37.7 million in 2024, then grew by 18.02% to $44.5 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for SRPT at $44.5 million in Q4 2025, $37.7 million in Q4 2024, and $44.4 million in Q4 2023.